Shane Thomas Gleason Sells 7,186 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,186 shares of the business’s stock in a transaction on Friday, May 30th. The shares were sold at an average price of $2.51, for a total transaction of $18,036.86. Following the transaction, the insider owned 1,079,601 shares of the company’s stock, valued at $2,709,798.51. This represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Price Performance

NYSE NSPR opened at $1.00 on Friday. The company has a market capitalization of $46.84 million, a PE ratio of -1.33 and a beta of 0.82. The company has a fifty day moving average of $1.38 and a 200 day moving average of $1.66. InspireMD, Inc. has a 1 year low of $0.97 and a 1 year high of $2.93.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Loop Capital set a $5.00 target price on shares of InspireMD in a research report on Tuesday, February 24th. Lake Street Capital set a $4.00 target price on shares of InspireMD in a research report on Monday, May 4th. Finally, Maxim Group started coverage on shares of InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective for the company. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $4.50.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NSPR. Creative Planning acquired a new position in shares of InspireMD in the second quarter worth about $44,000. Raymond James Financial Inc. raised its position in shares of InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after acquiring an additional 10,000 shares during the period. Rosalind Advisors Inc. raised its position in shares of InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock worth $5,196,000 after acquiring an additional 14,109 shares during the period. Soleus Capital Management L.P. raised its position in shares of InspireMD by 99.5% in the second quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock worth $4,282,000 after acquiring an additional 940,831 shares during the period. Finally, Courier Capital LLC raised its position in shares of InspireMD by 83.3% in the third quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock worth $133,000 after acquiring an additional 25,000 shares during the period. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD News Roundup

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.